ITEM VIEW

Can we predict and/or prevent type I diabetes?

dc.contributor.authorSandler, Malcolmen_ZA
dc.date.accessioned2011-03-18T14:57:20Z
dc.date.available2011-03-18T14:57:20Z
dc.date.issued1990
dc.identifier.issn2078-5135 (online)
dc.identifier.issn0256-9574 (print)
dc.identifier.urihttp://hdl.handle.net/10019.1/7343
dc.descriptionCITATION: Sandler, M. 1990. Can we predict and/or prevent type I diabetes? South African Medical Journal, 78:462-467.
dc.descriptionThe original publication is available at http://www.samj.org.za
dc.description.abstractThe highest risk for the development of type I diabetes resides with first-degree relatives of the diabetic proband, this risk being in the order of 2.9%, 6.6% and 4.9% for parents, siblings and children of the proband, respectively. The major genetic markers associated with the development of insulin-dependent diabetes mellitus (IDDM) is the possession of the HLA alleles DR3/DR4 and more recently the absence of aspartate in the 57th position on the beta-chain of the HLA DQ gene (HLA DQ beta Asp 57 negative). The most important auto-immune marker for predicting preclinical IDDM is the presence of high titres (greater than 40 Juvenile Diabetes Foundation units) of islet cell antibodies (ICA), while the finding of insulin auto-antibodies (IAA) is a good predictive marker in children less than 5 years of age. The presence in a susceptible individual of ICA plus IAA is a better predictor of impending IDDM than the presence of either of these two markers alone. Antibodies which precipitate an islet membrane protein (MW 64K) are highly sensitive and specific markers of preclinical IDDM. The presence of 64K antibodies may well be the most important predictive marker of impending IDDM in the future. The progressive decline of the first phase of insulin secretion in response to an intravenous glucose challenge is associated with the onset of IDDM within 18 months. Of the immunotherapeutic agents at present used in clinically manifest IDDM, azathioprine has been shown to be ineffective in increasing the remission phase, while the value of nicotinamide is controversial.(ABSTRACT TRUNCATED AT 250 WORDS)
dc.language.isoen
dc.publisherHealth & Medical Publishing Group
dc.subjectDiabetesen_ZA
dc.titleCan we predict and/or prevent type I diabetes?en_ZA
dc.typeArticle
dc.description.versionPublisher’s version
dc.rights.holderSouth African Medical Journal


Files in this item

Thumbnail

This item appears in the following Collection(s)

ITEM VIEW